MX2020004674A - Anticuerpos contra alfa-sinucleina y usos de los mismos. - Google Patents

Anticuerpos contra alfa-sinucleina y usos de los mismos.

Info

Publication number
MX2020004674A
MX2020004674A MX2020004674A MX2020004674A MX2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A MX 2020004674 A MX2020004674 A MX 2020004674A
Authority
MX
Mexico
Prior art keywords
synuclein
antibodies
aggregates
antibody
diagnosis
Prior art date
Application number
MX2020004674A
Other languages
English (en)
Inventor
Jinhyung Ahn
Sungwon An
Dongin Kim
Jaehyun Eom
Weonkyoo You
Jinwon Jung
Yeunju Kim
Yonggyu Son
Byungje Sung
Sang Hoon Lee
Bora Lee
Seawon Ahn
Youngdon Pak
Donghoon Yeom
Daehae Song
Original Assignee
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc filed Critical Abl Bio Inc
Publication of MX2020004674A publication Critical patent/MX2020004674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

La presente invención proporciona un anticuerpo anti-a-sinucleína que de manera preferencial reconoce agregados de a-sinucleína, y uso de detección, diagnóstico y/o tratamiento o prevención de diversas enfermedades causadas por acumulación de agregados de a-sinucleína y sus enfermedades de síntomas relacionadas usando el anticuerpo anti-a-sinucleína.
MX2020004674A 2017-11-17 2018-11-16 Anticuerpos contra alfa-sinucleina y usos de los mismos. MX2020004674A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588018P 2017-11-17 2017-11-17
US201862687848P 2018-06-21 2018-06-21
PCT/KR2018/014123 WO2019098763A2 (ko) 2017-11-17 2018-11-16 알파-시누클레인에 대한 항체 및 그 용도

Publications (1)

Publication Number Publication Date
MX2020004674A true MX2020004674A (es) 2020-08-13

Family

ID=66537805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004674A MX2020004674A (es) 2017-11-17 2018-11-16 Anticuerpos contra alfa-sinucleina y usos de los mismos.

Country Status (10)

Country Link
US (1) US20230279085A1 (es)
EP (1) EP3725802A4 (es)
JP (2) JP7173618B2 (es)
KR (1) KR102508933B1 (es)
CN (1) CN111356701B (es)
AU (2) AU2018370279B2 (es)
BR (1) BR112020009707A2 (es)
CA (1) CA3082559A1 (es)
MX (1) MX2020004674A (es)
WO (1) WO2019098763A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013953A2 (pt) * 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
PE20220516A1 (es) * 2019-06-14 2022-04-07 Abl Bio Inc ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO
EP4229082A1 (en) * 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
TW202309076A (zh) * 2021-05-12 2023-03-01 南韓商Ａｂｌ生物公司 用於治療α-突觸核蛋白病之抗體
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用
WO2024044709A2 (en) * 2022-08-24 2024-02-29 The Research Foundation For The State University Of New York Anti-monomethyl auristatin antibodies and antibody fragments
CN117607463B (zh) * 2024-01-23 2024-04-09 杭州华得森生物技术有限公司 一种循环肿瘤细胞egfr免疫显色检测试剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
CN106397588B (zh) 2010-02-26 2020-09-08 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
SI2723379T1 (sl) * 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof

Also Published As

Publication number Publication date
WO2019098763A2 (ko) 2019-05-23
JP2023017837A (ja) 2023-02-07
US20230279085A1 (en) 2023-09-07
AU2022252753A1 (en) 2023-01-19
CN111356701A (zh) 2020-06-30
WO2019098763A3 (ko) 2019-07-11
AU2018370279A1 (en) 2020-05-28
EP3725802A2 (en) 2020-10-21
CN111356701B (zh) 2023-11-21
JP7173618B2 (ja) 2022-11-16
JP2021503288A (ja) 2021-02-12
WO2019098763A9 (ko) 2019-08-29
BR112020009707A2 (pt) 2020-10-13
CA3082559A1 (en) 2019-05-23
EP3725802A4 (en) 2021-08-11
KR20190057004A (ko) 2019-05-27
KR102508933B1 (ko) 2023-03-13
AU2018370279B2 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
EA201992546A1 (ru) Средства на основе антител к cd33
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
CO2017006740A2 (es) Anticuerpos anti–cd79b
CL2017001090A1 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CL2017000111A1 (es) Moléculas con especificidad para cd45 y cd79
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
ECSP19018327A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
BR112016014731A2 (pt) Anticorpos anti-baff
BR112018071583A2 (pt) métodos para determinar dpp3 e métodos terapêuticos
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
CL2021000736A1 (es) Receptor de antígeno quimérico.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201992317A1 (ru) Композиции и способы для диагностики рака легких